Clozapine maintenance therapy in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 28, Issue 3, 2004, Pages 465-469

  Gaszner, Péter ^a   Makkos, Zoltán ^a  

^a NATIONAL INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Hungary)

Author keywords

CGIS; Clinical Global Impression Scale; Clozapine; D 2; Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision; Dopamine; DSM IV TR; Haloperidol; Long term maintenance therapy; Relapse; Schizophrenia; Side effect

Indexed keywords

CLOZAPINE; HALOPERIDOL;

ADOLESCENT; ADULT; ARTICLE; CATATONIC SCHIZOPHRENIA; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIRIUM; DROWSINESS; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEBEPHRENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PARANOID SCHIZOPHRENIA; PARKINSONISM; QUALITY OF LIFE; RELAPSE; REMISSION; RESIDUAL SCHIZOPHRENIA; RISK BENEFIT ANALYSIS; SALIVATION DISORDER; SCHIZOAFFECTIVE PSYCHOSIS; SIDE EFFECT; SOMNOLENCE; STATISTICAL ANALYSIS; TARDIVE DYSKINESIA; TREATMENT OUTCOME; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HALOPERIDOL; HUMANS; LONG-TERM CARE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHIATRIC STATUS RATING SCALES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 1842828871     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2003.11.011     Document Type: Article

References (15)

1. Bunney B.S. Clozapine: a hypothesised mechanism for its unique clinical profile. Br. J. Psychiatry. 160(Suppl. 17):1992;17-21.
2. DSM-IV-TR Diagnostic Criteria from DSM-IV-TR. 2000;American Psychiatric Association (APA), Washington.
3. Fitton A., Benfield P. Clozapine, an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia. Pharmacoeconomics. 4:1993;131-156.
4. Gaszner P., Makkos Z. Clozapine treatment of schizophrenia. Neuropsychopharmacol. Hung. 1:1999;28-30.
5. Gaszner P., Makkos Z., Kosza P. Agranulocytosis during clozapine therapy. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2002;603-607.
6. Gerlach J., Lublin H., Peacock L. Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1 and D2 dopamine antagonists. Neuropsychopharmacology. 14(Suppl. 3):1996;35-39.
7. Gross H., Langner E., Pfolz H. Clozapine in long-term therapy of chronic schizophrenia. Arzneim.-Forsch. 24:1974;987-989.
8. Helmchen H. Clinical experience with clozapine in Germany. Psychopharmacology (Berl.). 99:1989;80-83. (Suppl.).
9. Hummel B., Ditmann S., Forsthoff A., Matzner N., Amann B., Grunze H. Clozapine as add-on medication in the maintenance treatment of bipolar and schizoaffective disorders. Neuropsychobiology. 45(Suppl. 1):2002;37-42.
10. Lindstrom L.H. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr. Scand., Suppl. 380:1994;74-76.
11. Makkos Z., Csernus I., Kosza P., Gaszner P. Agranulocytosis and clozapine therapy. Neuropsychopharmacol. Hung. 2:2000;43-44. (Suppl.).
12. Meltzer H.Y. Treatment of suicidality in schizophrenia. Ann. N.Y. Acad. Sci. 932:2001;44-58.
13. Meltzer H.Y., Lee M.A., Ranjan R. Recent advances in the pharmacotherapy of schizophrenia. Acta Psychiatr. Scand., Suppl. 384:1994;95-101.
14. Meltzer H.Y., Alphs l., Green I., Altamura A.C., Anand R., Bertoldi A., Bourgeois M., Chouinard G., Islam M.Z., Kane J., Krishnan R., Lindenmayer J.-P., Potkin S. Clozapine treatment for suicidality in schizophrenia (InterSePT). Arch. Gen. Psychiatry. 60:2003;71-80.
15. Stahl S.M. Essential psychopharmacology. Neuroscientific Basis and Practical Application. 2000;University Press, Cambridge.